MPN-RC Monthly Publication

**Title:*Immunotherapeutic targeting of calreticulin mutant myeloproliferative neoplasms***

Authors: Charles Hertz, Nikolaos Spyrou, Ronald Hoffman, Cansu Cimen Bozkus, Nina Bhardwaj, Douglas Tremblay, Marina Kremyanskaya, John Mascarenhas

Full Article

Consortium Member of the Month

Our consortium member of the month for the month of September goes to Anna Blangiardo from Mount Sinai Health System!

Anna Blangiardo

Senior Clinical Research Coordinator

Anna became the primary coordinator for the MPN-RC 120 and MPN-RC 122 studies at Mount Sinai in early 2025. She played an important role in data cleaning efforts and resolved a high volume of queries in preparation for data locks for both studies earlier this year. She also dedicated additional time and effort to preparing source documents for monitors to facilitate the review and verification of a significant amount of historical data that had accumulated prior to the studies transitioning to her. Her dedication and contributions to these studies and the consortium are greatly appreciated!

Nominated by: Gabriela Bello

Anna, thank you so much for all of the phenomenal work you have done for the consortium.

Keep up the great work!

ASH Conference 2025

(Left to Right: Gaby Bello, Carly Sullivan, Ashley Yu) The Mount Sinai group from the MPN Research Consortium attended the American Society of Hematology 2025 Conference in Orlando, Florida.
Dr. Xiaoli Wang presents her ASH abstract “Therapy resistance and disease relapse in patients with MPN-blast phase are associated with clonal evolution and transcriptomic changes in MPN- blast phase stem cells”. View the abstract here!
Dr. Andrew Kuykendall presents his ASH abstract “A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1”. View the abstract here!
(Left to Right: Md. Babu Mia, Noushin Rahnamay, Dr. Bridget Marcellino, and Dr. Raajit Rampal) The Mount Sinai and Memorial Sloan Kettering group from the MPN Research Consortium attended the American Society of Hematology 2025 Conference in Orlando, Florida.

ASH Abstracts

Marina Kremyanskaya, MD,PhD

Phase II study of reparixin in patients with myelofibrosis. myeloproliferative neoplasms research consortium (MPN-RC) 120 trial

Full ASH Abstract
John Crispino, PhD,MBA

Menin inhibition as a new therapeutic option for the myeloproliferative neoplasms

Full Ash Abstract
John Mascarenhas, MD

Bone marrow adipocytes (BMA) as a novel biomarker of molecular response in patients with essential thrombocythemia (ET) and polycythemia vera (PV) treated with pegylated interferon alfa-2A

Full ASH Abstract
Andrew Kuykendall, MD

A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1

Full Ash Abstract
Min Lu, MD,PhD

Myelofibrosis stem cell fitness requires microenvironmental cell interactions

Full ASH Abstract
Xiaoli Wang, MD,PhD

Therapy resistance and disease relapse in patients with MPN-blast phase are associated with clonal evolution and transcriptomic changes in MPN- blast phase stem cells

Full Ash Abstract
MD Babu Mia, PhD

Single cell transcriptional profiling reveals distinct subsets of human megakaryocytes in myelofibrosis

Full ASH Abstract